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AbstrACt
Introduction Coronary artery bypass grafting (CABG) 
surgery is known to improve vascular function and 
cardiac- related mortality rates; however, it is associated 
with high rates of postoperative cognitive decline and 
delirium. Previous attempts to prevent post- CABG cognitive 
decline using pharmacological and surgical approaches 
have been largely unsuccessful. Cognitive prehabilitation 
and rehabilitation are a viable yet untested option for CABG 
patients. We aim to investigate the effects of preoperative 
cognitive training on delirium incidence, and preoperative 
and postoperative cognitive training on cognitive decline at 
4 months post- CABG.
Methods and analysis This study is a randomised, 
single- blinded, controlled trial investigating the use of 
computerised cognitive training (CCT) both pre- CABG 
and post- CABG (intervention group) compared with usual 
care (control group) in older adults undergoing CABG in 
Adelaide, South Australia. Those in the intervention group 
will complete 1–2 weeks of CCT preoperatively (45–60 min 
sessions, 3.5 sessions/week) and 12 weeks of CCT 
postoperatively (commencing 1 month following surgery, 
45–60 min sessions, 3 sessions/week). All participants 
will undergo cognitive testing preoperatively, over their 
hospital stay including delirium, and postoperatively for 
up to 1 year. The primary delirium outcome variable will 
be delirium incidence (presence vs absence); the primary 
cognitive decline variable will be at 4 months (significant 
decline vs no significant decline/improvement from 
baseline). Logistic regression modelling will be used, 
with age and gender as covariates. Secondary outcomes 
include cognitive decline from baseline to discharge, and 
at 6 months and 1 year post- CABG.
Ethics and dissemination Ethics approval was obtained 
from the Central Adelaide Local Health Network Human 
Research Ethics Committee (South Australia, Australia) and 
the University of South Australia Human Ethics Committee, 
with original approval obtained on 13 December 2017. It 
is anticipated that approximately two to four publications 
and multiple conference presentations (national and 
international) will result from this research.
trial registration number This clinical trial is registered 
with the Australian New Zealand Clinical Trials Registry 
and relates to the pre- results stage. Registration number: 
ACTRN12618000799257.
IntroduCtIon
Coronary artery bypass grafting (CABG) is 
one of the main treatments used to revas-
cularise patients suffering from severe coro-
nary artery disease, where coronary vessels 
are dangerously stenosed due to athero-
sclerotic plaque build- up.1 Coronary artery 
narrowing commonly results in myocardial 
ischaemia, which affects cardiac output. This 
can lead to reduced blood perfusion of the 
brain, contributing to cognitive impairment.2 
The cognitive domains most affected by 
the presence of coronary artery disease are 
psychomotor speed, memory and executive 
function.3 Impairments in these domains are 
characteristic of vascular dementia, as similar 
pathological mechanisms are likely at play.4
strengths and limitations of this study
 ► This study will be the first to deliver cognitive train-
ing preoperatively and postoperatively to older pa-
tients undergoing coronary artery bypass grafting 
(CABG) surgery.
 ► The results of this study may provide a prevention 
strategy for cognitive impairments, including delir-
ium, observed post- CABG surgery.
 ► We are limited by a two- group design (control vs 
intervention) due to feasibility issues; therefore, the 
effects of only pre- CABG and only post- CABG cogni-
tive training cannot be investigated.
 ► The generalisability of the study will be limited 
to Adelaide (South Australia) metropolitan CABG 
patients.
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While CABG surgery is known to improve cardiac 
function and mortality,5 CABG is also associated with a 
high risk of developing postoperative cognitive impair-
ment. A recent meta- analysis by our group investigated 
cognitive outcomes of CABG patients using a cross- 
sectional approach (percentage at specific timepoints) 
and reported that postoperative cognitive impairment 
was present in 43% of patients acutely (up to 4 days post-
operatively).6 This was lower (25%) in patients 6–12 
months following surgery and higher (up to 40%) up to 
5 years postoperatively.6 In our meta- analysis, we found 
that within 7.5 years of CABG, 31% of patients had devel-
oped dementia (when rigorous diagnostic methods were 
used),6 compared with the population prevalence of 
around 7% in Australasians aged ≥60 years old.7
Delirium is also relevant to this patient group. It is a 
common form of postoperative cognitive dysfunction 
characterised by acute and fluctuating deficits in atten-
tion (or broader cognitive impairments) and arousal.8 
Depending on cardiac surgery type, postoperative 
delirium incidence has been reported as high as 72%,9 
with our meta- analysis revealing the incidence after 
CABG was 24% when appropriate diagnostic tools were 
used.6 The presence of delirium in late life is associated 
with a doubling of cognitive decline,10 leads to functional 
impairments, mortality11 and greatly increases the risk 
(OR 8.7) of dementia.11
Given CABG is such a common procedure (180 476 in 
the USA in 201612), reducing the incidence of postop-
erative cognitive impairment and delirium is a research 
priority. The worldwide cost of dementia in 2016 was 
estimated to be US$818 billion and was projected to 
increase substantially in the following years.13 Therefore, 
it is crucial for the economy to reduce or delay cogni-
tive impairments (including dementia) in late life, and 
targeting post- CABG cognitive dysfunction is a new prom-
ising strategy.
Prior research to prevent post- CABG cognitive impair-
ment has met with little success, either through the alter-
ation of surgical techniques,14 15 or pharmacological and 
anaesthetic interventions.16–18 More advanced surgical 
methods such as increasing intraoperative systemic perfu-
sion and hypothermia have shown some evidence of ther-
apeutic efficacy but require expertise and technology 
not routinely available in hospitals.19 A novel approach 
is to consider that cognitive impairment in older adults 
comes about from the deterioration of multiple systems 
in a complex interplay.20 Interactions between general 
anaesthesia, cardiac output and reductions in mental 
abilities could be targeted by directly challenging cogni-
tive systems. For example a recent study investigating the 
effect of postoperative computerised cognitive training 
(CCT) in 51 CABG patients found improvements in the 
trained domains of memory and attention (ƞ2=0.50) at 
3 months postoperatively in the intervention group, as 
compared with controls.21
CCT is an inexpensive, safe and scalable method of 
cognitive intervention which can be modified to target 
singular or multiple cognitive domains, and has been 
shown efficacious for cognition in older populations with 
and without cognitive impairments and in those with 
heart failure.22–26 A meta- analysis by Hill and colleagues22 
reported a moderate effect size (g=0.35) on overall cogni-
tion in older adults with mild cognitive impairment. 
Healthy older adults and those with Parkinson’s disease 
still benefit from CCT, although the overall pooled effect 
is not as large (g=0.22–0.23).22 25 CCT has also been 
shown effective in patients with heart failure, significantly 
improving processing speed.24 26 The idea of optimising 
perioperative brain health, using cognitive training, is 
fast becoming recognised as an important area of clin-
ical and public health research.27 Recently two studies 
investigating non- cardiac patients (lung transplant and 
knee arthroplasty) have shown improvement in neuropsy-
chological testing28 29 and reductions in depression and 
anxiety29 following postoperative CCT.
To date, preoperative cognitive training has been used 
in three studies with both cardiac30 and non- cardiac 
patients.31 32 In gastrointestinal patients, a cognitive inter-
vention delivered preoperatively decreased the incidence 
of acute (1 week) cognitive impairments postoperatively 
(16%) when compared with the control group (36%).31 
However, no significant effects of presurgery cognitive 
training were found in feasibility trials investigating 
cardiac patients,30 nor a mixed group of gastrointestinal, 
urological, spine and hepatobiliary surgery patients,32 on 
either surgery- related cognitive impairment or delirium 
incidence. However, this may be due to the method of 
cognitive training administration, with each session 
being relatively short (<30 min) and home- based (unsu-
pervised). Sessions of this format have been shown to 
be ineffective, especially if home- based training is not 
supplemented with supervised sessions.25
This project will deliver cognitive training preoper-
atively and postoperatively in older patients aged ≥65 
years undergoing CABG. Reducing postoperative cogni-
tive impairments, including delirium, could have wide- 
reaching effects. Delirium is not only a risk factor of 
mortality but also prolongs admissions, which affect both 
the patient and the healthcare system financially.33 34 
Additionally, better long- term cognitive outcomes may 
lead to increased healthcare access for older patients 
being considered for surgery, where they otherwise may 
have been declined due to cognitive concerns.
We aim to investigate the effect of remotely supervised 
CCT on cognitive outcomes following CABG surgery in 
older adults. Specifically, our primary aims are to deter-
mine the effect of (1) pre- CABG CCT on the incidence 
of postoperative delirium and (2) pre- CABG and post- 
CABG CCT on cognitive decline (as compared with base-
line) at 4 months. Our secondary aims are to determine 
the effect of (1) pre- CABG CCT on cognitive decline (as 
compared with baseline) at discharge and (2) pre- CABG 
and post- CABG CCT on cognitive decline (as compared 
with baseline) at 6 months and 1 year postsurgery. Addi-
tional exploratory aims are to determine the influence 
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Figure 1 Study timeline highlighting the time of assessments and interventions, specific to control and intervention. 
Assessment sessions contain cognitive battery and other additional assessments (see table 1). CB, cognitive battery; CT, 
cognitive training; DB, daily delirium battery in hospital; UC, usual care.
of CCT on delirium severity and subtype, as well as the 
predictors of cognitive training response in older adults 
undergoing elective CABG surgery, including factors 
such as depression, education, age, baseline cognition 
and perioperative health.
MEthods And AnAlysIs
study design
This study is reported in alignment with the statements 
of the Consolidated Standards of Reporting Trials and 
the Standard Protocol Items: Recommendations for 
Interventional Trials.35 36 This study is a single- blinded, 
randomised controlled trial with longitudinal follow- up 
comparing remotely supervised CCT (intervention 
group) with usual care (control group). Cognitive func-
tion will be measured prior to surgery (baseline) and 
at discharge, 4 months (end of intervention), 6 months 
and 1 year postoperatively. The presence of delirium will 
be measured (daily) in- hospital postoperatively and at 
discharge (see figure 1).
Patient and public involvement
Clinical partners were involved in the study design; 
however, there was no patient and public involvement.
Primary and secondary outcomes
The effect of cognitive training will be assessed, through 
group comparison (control vs intervention), at multiple 
timepoints (as compared with baseline/pre- CABG, ie, 
change from baseline at multiple timepoints) throughout 
the study. Our primary outcome for cognitive decline 
(from baseline) is 4 months post- CABG, which follows 
cessation of the CCT intervention. The primary outcome 
for delirium will be presence (vs absence) in- hospital 
(including discharge assessment) post- CABG. Cognitive 
decline (from baseline) at discharge and at 6 months and 
1 year post- CABG is also being investigated as secondary 
outcomes. Additional analyses will be performed to assess 
the exploratory aims of the study.
setting
This research is ongoing and conducted at multiple 
sites (hospital, home, university). Recruitment and post- 
CABG testing until discharge are conducted at the Royal 
Adelaide Hospital (RAH) in the Cardiothoracic Surgery 
Unit and in the Intensive Care Unit. The RAH is a public 
hospital located in Adelaide central business district 
(CBD) providing services primarily to those in the central 
metropolitan region and a substantial number of people 
from rural and remote areas. Baseline and discharge 
testing are conducted at participants’ homes. Follow- up 
testing sessions at 4 months, 6 months and 1 year post- 
CABG are conducted at participants’ homes or at a 
University of South Australia metropolitan campus.
Participants
Inclusion criteria
 ► Persons, male or female, who have consented to 
undergo elective CABG surgery at the RAH (note: 
additional concomitant cardiac surgeries will not 
exclude patient, such as CABG plus mitral valve 
replacement).
 ► Aged 65 years and over.
 ► Proficient English speakers.
 ► Have normal vision and hearing with or without the 
use of aids.
 ► Live within the metropolitan boundaries of Adelaide 
(Development Act 1993) or within a 1- hour drive 
from the CBD.
Exclusion criteria
 ► Known learning disabilities, a dementia diagnosis or 
a significant neurological/psychiatric diagnosis (all 
factors will affect ability to perform assessments).
 ► History of pharmaceutical cancer treatment within 
the past 5 years, excluding pure surgical treatment 
(cancer treatment is known to negatively affect 
cognition37).
 ► Suffered a stroke within the past year (many stroke- 
related cognitive impairments subside within a year38).
 ► Currently practising cognitive training (will interfere 
or muddle cognitive training effects).
 ► Additionally, those who are not enrolled to complete 
baseline testing at least 5–6 days prior to their surgery 
will be excluded (need to complete a minimum of 
three preoperative cognitive training sessions).
Sample size
Using the G*Power statistical analysis software,39 a 
priori sample size was calculated based on a published 
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meta- analysis effect size (Hedges’ g=0.35) of the overall 
effect of CCT on cognitive outcomes (in adults aged ≥60 
years who presented with mild cognitive impairment).22 
The selection of this effect size for cognitive training 
(previously mentioned meta- analysis) was based on the 
cognitive status distribution of those already recruited 
within our study, with over half presenting with cognitive 
impairment at baseline (Addenbrooke’s Cognitive Exam-
ination (ACE- III) score ≤88). This power analysis is based 
on the primary study outcomes: presence of cognitive 
decline at 4- month follow- up and presence of delirium 
following surgery. With g=0.35, power=0.80 and α=0.05, 
the computed sufficient sample size for comparing pres-
ence versus absence of delirium or cognitive decline 
using logistic regression was n=94 (47 per group); there-
fore, in order to account for participant attrition during 
follow- up, a total of 120 participants (60 per group) will 
be recruited.
Recruitment and feasibility
Patients are recruited during their presurgery clinic day at 
the RAH, approximately 1–3 weeks prior to CABG surgery. 
Presurgery clinic days are designed to educate the patient 
about their upcoming surgery and the possible outcomes 
of the surgery, and allows nursing, pharmacy, medical 
and anaesthetic staff to meet with the patients and gain 
any further necessary information (lung function, height, 
weight and ECG). Patients are informed of the study 
face to face (or via a phone call if not seen during the 
presurgery clinic) during the afternoon session; those 
interested are then screened for inclusion and if eligible 
and interested are scheduled for their baseline session 
(informed consent process is conducted during baseline 
session). As recruitment is under way, the current rate 
is approximately 25 participants a year (27 participants 
from May 2018 to July 2019). To ensure numbers are met, 
active recruitment will be conducted for approximately 
4.5 years in total.
Honoraria
Participants will receive a total of $100 (5×$20) worth 
of vouchers across the duration of the study. The initial 
voucher is supplied to participants after the conclusion 
of their baseline testing session, prior to their surgery. 
The remaining four vouchers will be supplied to partic-
ipants after completion of the discharge and at 4- month, 
6- month and 1- year post- CABG follow- up sessions. Hono-
raria are being used in this study to cover time and other 
costs associated with participation.
Measures
Cognitive battery
Cognition is assessed with the ACE- III and multiple tests 
from the Cambridge Neuropsychological Test Automated 
Battery (CANTAB). The ACE- III is a widely used global 
cognition examination designed to screen for dementia. 
It assesses attention, language, verbal memory and visu-
ospatial function and is scored out of 100 (higher scores 
indicate better cognition). The two clinical cut- offs show 
high sensitivity and specificity: mild cognitive impair-
ment 88 (sensitivity=1.0; specificity=0.96) and dementia 
82 (sensitivity=0.93; specificity=1.0).40 Additionally, the 
ACE- III has alternate versions (all used within the study), 
allowing it to be used for longitudinal testing. The ACE- 
III score will be used to characterise and provide clinical 
meaning, at all study timepoints, categorising partici-
pants as normal, mild cognitive impairment or dementia 
according to clinical score cut- offs.
The CANTAB connect system provides a portable neuro-
psychological testing battery which can detect changes in 
multiple cognitive domains. The CANTAB testing battery 
used focuses on cognitive domains we know to be affected 
most by coronary artery disease, including psychomotor 
speed, memory and executive function.3 This allows us 
to detect smaller changes in specific cognitive domains, 
unlike the global cognition score from the ACE- III. Addi-
tionally, the CANTAB system contains parallel versions of 
tests which minimise practice effects of the tasks within 
longitudinal studies. The specific tests used will be the 
Motor Orientation Task (MOT), Reaction Time (RTI), 
Paired Associated Learning (PAL), Spatial Working 
Memory (SWM) and One Touch Stockings of Cambridge 
(OTS). Data from CANTAB will be converted into one 
main outcome measure for each test and used to inves-
tigate cognitive decline (over time). Data from the 
MOT will not be analysed as this test is purely a tablet 
familiarisation task. It should be noted that in the initial 
cognitive assessment during baseline testing, CANTAB is 
conducted twice (practice trials approximately 15 min, 
then full assessment including practice trials), serving as a 
double baseline in an attempt to minimise practice effects 
of the tasks.
Delirium battery
The presence of delirium (primary aim) and the severity 
and motor subtype (characterisation and exploratory 
purposes) are captured with the Confusion Assessment 
Method (CAM) and CAM for the Intensive Care Unit 
(CAM- ICU) version and the Memorial Delirium Assess-
ment Scale (MDAS). Following surgery, while patients 
are in the intensive care unit, the CAM- ICU is used to 
diagnose the presence of delirium. The CAM- ICU is an 
adaptation of the original CAM which has been validated 
and has high sensitivity and specificity in those who are 
critically ill or those who receive multiple psychoactive 
medications (ie, postoperative patients).41 While on the 
ward a daily MDAS interview is conducted to ascertain 
delirium severity, as the MDAS is not intended for diag-
nostic purposes.42 43 This interview informs the scoring 
of the CAM (questions used to score the CAM are 
embedded in the MDAS interview), providing a dichot-
omous delirium presence outcome. On weekends, when 
delirium assessments are not conducted by research team 
members, a chart- based review tool developed by Inouye 
and colleagues44 is used to ascertain the presence of any 
delirium episodes. We acknowledge that the use of a 
5Greaves D, et al. BMJ Open 2020;10:e034551. doi:10.1136/bmjopen-2019-034551
Open access
chart review tool is not as thorough as our daily assess-
ment battery and may result in inaccuracies (likely under-
estimation) in determining delirium.
The CAM is divided into four main features of delirium: 
(1) acute onset and fluctuating course; (2) inatten-
tion; (3) disorganised thinking; and (4) altered level of 
consciousness. To assess altered level of consciousness/
arousal, two scales were selected. The Richmond Agita-
tion Sedation Scale is used in the ICU, while the Obser-
vational Scale of Level of Arousal is used on the ward. 
The primary outcome (presence vs absence of delirium) 
is considered as positive delirium, both in the ICU and 
during the ward stay, when CAM features 1 and 2 and 
either 3 or 4 are present. A positive delirium diagnosis, 
or acknowledgement of delirium in chart review, at any 
point during the hospital stay is considered as presence of 
delirium. All members conducting delirium assessments 
were trained by qualified geriatricians (AB and DHJD).
For characterisation of delirium and for explor-
atory purposes of cognitive training effects, the severity 
and subtype of delirium are also assessed. The MDAS 
interview contains a cognitive assessment which allows 
delirium items of memory impairment, impaired digit 
span and inattention to be easily quantified, as well as 
more open- ended questions regarding patients’ experi-
ences to assess sleep–wake cycle, perceptual disturbance 
and disorganised thinking. This allows a severity score out 
of 30 (higher scores indicate more severe symptoms) to 
be generated. Motor subtype (hypoactive, hyperactive, 
mixed or no subtype) of delirium, when present, is classi-
fied using a checklist created by Meagher.45
Computerised cognitive training
Given cognitive training gains tend to be most profound 
in trained domains, the CCT intervention used in this trial 
is based on HappyNeuron Pro, which provides extensive 
practice on the cognitive domains most affected by heart 
failure, namely psychomotor speed, attention, memory 
and executive function.2 4 46 47 In addition, this program 
offers a clinical backend, which provides remote moni-
toring of performance and adherence and thus facili-
tates remote supervision aimed at maximising participant 
engagement.
For participants in the intervention group, the CCT 
intervention is home- based and conducted on either a 
participant’s personal laptop or on a supplied university- 
owned laptop and Wi- Fi dongle. The duration of the 
sessions is approximately 45–60 min of completed cogni-
tive training (allowing for short breaks). The session 
frequency pre- CABG is every other day (3.5 times a week 
on average), while post- CABG this frequency decreases to 
three times a week (see figure 1). This dosage has been 
established as the most effective in a meta- analysis, where 
sessions less than 30 min in length or more than three 
sessions a week were found less efficacious than longer, 
less frequent sessions.25
Pre- CABG cognitive training begins following baseline 
testing, conducted at the participant’s home, commonly 
1–2 weeks prior to scheduled CABG. The initial session 
(during baseline) and the following session are instructed 
and supervised, with an emphasis being placed on partici-
pants’ understanding, strategy and competence of system 
use. Participants complete approximately 45–60 min of 
cognitive training every other day over a 2- week period 
following baseline testing (minimum of three sessions). 
All participants are supervised for at least one session a 
week as well as contacted weekly via phone; these calls are 
in place to help participants with any technical problems 
and to assess their weekly pain score.
Post- CABG cognitive training begins 1 month following 
surgery, allowing enough recovery time (timing decided 
after consultation with study clinical partners). This 
second regimen is longer in duration (compared with 
pre- CABG) and is conducted for 12 weeks, still with 
45–60 min sessions three times a week (approximately 
27–30 hours). Between their pre- CABG and post- CABG 
interventions, participants are advised not to access the 
CCT program. The initial session is yet again super-
vised; following this, one session per week is supervised. 
Weekly follow- up phone calls are conducted identical to 
the pre- CABG intervention. Following the completion 
of the intervention, participants will be given access to 
the cognitive training system if they request it until the 
completion of the study (1 year postoperatively); however, 
there will be no scheduled sessions.
When required (due to participant struggles or inter-
vention inactivity), an additional face- to- face supervised 
session is organised. However, when inactivity or a lack 
of adherence is common during the post- CABG interven-
tion, participant involvement in the intervention is ceased. 
An acceptable adherence cut- off has been set as comple-
tion of 66% (standard within the literature) of prescribed 
training sessions.48 If a participant is not reaching this 
target, considering holidays (Christmas/Easter) and 
any relevant personal reasons, they are notified of the 
consequences of not improving their adherence to the 
accepted rate. If the lack of adherence continues, they 
are terminated from the intervention but offered to stay 
enrolled in the study for follow- up (however, their data 
will not be used in group comparisons).
Participants randomised to the control group expe-
rience usual care, with no intervention both pre- CABG 
and post- CABG. However, these participants are still 
contacted via phone on a weekly basis to complete their 
pain assessments.
Procedure
Participants are randomised into either control or inter-
vention and provide informed consent prior to the 
commencement of the first data collection session (base-
line). Approximately 1–2 weeks prior to their surgery 
(minimum 5–6 days), baseline testing (up to 3–4 hours) 
is conducted, including demographics, psychological 
(depression), general questionnaires (health, well- being, 
quality of life), pain measures and cognitive assessment, 
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along with the commencement of their intervention 
programme, if in the intervention group (see table 1).
Information regarding perioperative factors are 
recorded, including anaesthetics, time on bypass and 
aortic cross- clamp time. Following surgery, clinical data 
(bedside notes, medicine charts) and delirium episodes 
are monitored daily until discharge by a researcher. 
Following discharge (within 7 days of leaving the RAH), 
a cognitive assessment identical to baseline is conducted 
by a researcher who is blind to group allocation, at the 
participant’s home (discharge testing). A home visit 
was decided as the most practical and feasible method 
of collecting discharge data after consultation with clin-
ical partners involved in the study. Finally, cognitive 
assessments are performed during follow- up sessions 
at approximately 4 months (on postoperative interven-
tion programme completion), 6 months and 1 year post- 
CABG, at a University of South Australia metropolitan 
campus or the participant’s home.
Randomisation
Once a potential participant has confirmed their interest, 
they are booked in for their baseline session. Once 
scheduled, they are allocated a study identification (ID) 
number (next sequential number after the previous 
participant) and randomised into either control or inter-
vention (50:50) based on this ID number. A randomis-
ation list was generated ( www. randomization. com) prior 
to study commencement, with specification ensuring that 
for every 10 participants, 5 will be randomised to each 
group. This list is only accessible by one member of the 
research team, who only informs research team members 
of an individual participant’s group allocation when 
needed.
Blinding
The blinding procedure within this study is complex, as 
multiple research team members are involved in base-
line sessions and providing face- to- face cognitive training 
sessions to participants. At baseline, two research team 
members are always present for the session, not only for 
safety but also to ensure neuropsychological tests are 
administered by a blinded (to group allocation) research 
team member. One of the team members present at 
baseline, who is not blinded, conducts the consent 
process for the participant, while the other researcher 
is not present. The other team member, who is blinded, 
returns following consent and administers the cognitive 
test battery. This team member by the conclusion of the 
baseline session is no longer blinded, as the participant 
will either complete a cognitive training session at the 
end of their baseline testing or not. Delirium assessments 
in hospital are always conducted by a researcher who is 
blinded to the group allocation of the participant (this 
researcher never attends baseline sessions). Additionally, 
all discharge and follow- up assessments are conducted by 
a research team member who is blinded to group alloca-
tion. In this study, separate consent forms are used for 
each group (different consent forms for those in control 
vs intervention). Therefore, the participants are blinded 
to the presence of other study groups.
data analysis
To determine the cognitive effects of CCT on delirium inci-
dence and cognitive decline post- CABG, a per- protocol 
analysis method will be employed, where only data from 
participants who completed ≥66% of prescribed CCT will 
be included in the primary analyses (not applicable to 
the control group).48 It is known that using this approach 
can bring about problems such as sample biases, reduced 
sample size and limited generalisability.49 Yet, due to this 
study being the first of its kind, it is important to deter-
mine the efficacy of the intervention as described, which 
will provide a platform for future and larger research 
projects (which could incorporate intention- to- treat 
approaches).49 Additionally, due to the non- linear nature 
of cognitive function from pre- CABG to post- CABG, no 
missing data approaches (eg, carry one forward or growth 
curve) would be suitable. This non- linearity is evident in 
our recent meta- analysis, where cognitive impairment is 
present in 19% of CABG patients preoperatively, then 
postoperatively increases to 43% acutely, improves to 19% 
at 4–6 months, then deteriorates to 40% at 1–5 years.6 For 
our primary analyses (delirium: delirium presence; cogni-
tive decline: 4 months), we will therefore only include 
participants without missing data. For all analyses, effect 
sizes will be reported and discussed.
Primary and secondary outcomes
Delirium
Delirium (presence vs absence across hospital stay) will be 
the outcome variable in a logistic regression, with group 
membership (control vs intervention) as a predictor vari-
able, and age and gender as covariates. Sensitivity analyses 
will be run with additional covariates, including baseline 
cognition (ACE- III score) and depression, to ensure any 
effects are not due to residual confounding, as these 
factors are related to delirium incidence.
Cognitive decline
Cognitive decline will be calculated using the Reliable 
Change Index (RCI) method, across the four CANTAB 
tests (main outcome measure will be used for RTI, PAL, 
SWM and OTS). This method was recommended to be 
used for future research investigating cognitive decline 
in our recent meta- analysis.6 The RCI method reflects 
individual change between two timepoints (from base-
line to follow- up timepoint), relative to the whole sample 
data while considering practice effects of the test. Specif-
ically, for each main test outcome, for each of the four 
CANTAB tests (RTI, PAL, SWM and OTS), the change 
in the participant’s pre- CABG to post- CABG test score is 
divided by the SE of the difference between the two test 
scores. Significant cognitive decline of an individual will 
be considered if a score of ≥−1.64 in ≥1 of the four tests 
is present, resulting in a dichotomous variable for each 
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participant (decline vs no decline/improvement). For 
the primary cognitive outcome at 4 months post- CABG, 
cognitive decline (decline vs no decline/improved) will 
be analysed by logistic regression with group membership 
(control vs intervention) as the predictor variable, and 
covariates of age and gender. Sensitivity analyses will be 
run with additional covariates including baseline cogni-
tion (ACE- III score) and depression, to ensure any effects 
are not due to residual confounding, as these factors are 
related to cognitive decline. For the secondary outcomes 
of all other follow- up sessions (discharge, 6 months and 
1 year), cognitive decline at each timepoint (always 
compared with pre- CABG cognition) will be used in sepa-
rate logistic regressions, with group membership (control 
vs intervention) as the predictor variable, and covariates 
of age and gender.
Exploratory delirium analyses
Additional delirium outcomes (other than presence vs 
absence) will be assessed, including severity, duration 
of episode and motor subtype, with the same predictors 
described in previous analyses. Delirium severity (MDAS 
score) and days spent in a delirium episode will be inves-
tigated using linear regression, and delirium motor 
subtype (hypoactive/hyperactive/mixed) will be investi-
gated using multinominal logistic regression. These anal-
yses will be conducted to investigate whether cognitive 
training affects delirium characteristics (as opposed to 
presence).
Exploratory cognitive decline analyses
To identify significant predictors of response to cogni-
tive training, a series of univariate linear regressions will 
be conducted with the outcome being cognition change 
(RCI scores, as a continuous variable, calculated using 
CANTAB data for each participant at each timepoint), 
and predictor variables will include baseline dementia 
risk, apolipoprotein E4 (APOE4) genotype, depression, 
pain, delirium, gender, age, cardiovascular risk (choles-
terol, glucose, blood pressure), medical history, quality of 
life and disability, body mass index, waist to hip ratio, waist 
circumference, medications, education, baseline cogni-
tion (ACE- III score), and perioperative factors (anaes-
thetics, time on bypass, time aorta clamped, number of 
bypasses, surgical complications). These analyses will be 
conducted on data obtained at discharge and at 4- month, 
6- month and 1- year follow- up separately.
Additionally, to investigate the presence of a dose 
response regarding CCT, a univariate linear regression will 
be conducted with the outcome being cognitive change 
(individual participant RCI scores, described previously) 
and the predictor variable of CCT training dose (total 
CCT minutes). Separate analyses will be conducted for 
(1) preoperative CCT training dose as compared with 
discharge cognitive change data, and (2) postoperative 
CCT training dose as compared with 4- month, 6- month 
and 1- year follow- up data separately.
The cognitive outcomes investigated in these analyses 
will be conducted on the data of participants who meet 
the standardised adherence cut- off of 66%. It should be 
noted that these additional analyses are exploratory and 
aim to establish effect sizes for future studies and will only 
be conducted on data obtained from the intervention 
group.
EthICs And dIssEMInAtIon
Informed consent
Participants interested and eligible are provided with 
both written and verbal information regarding the study 
by a study researcher (see online supplementary consent 
forms for control and intervention participants). The 
participants are reassured that the decision to participate 
or not will not influence the care provided to them at the 
RAH. Participants who present with a clinical diagnosis 
of dementia or learning disability are not eligible for the 
study, and therefore all potential participants should have 
the ability to give informed consent.
All participants reconsent at the 6- month and 1- year 
follow- up sessions. Again, participants are provided with 
both written and verbal information regarding the study 
by a researcher. If participants, since the last consent 
process, have been clinically diagnosed with dementia, 
or have developed a disability leaving them unable to 
consent for themselves, then a person responsible for the 
participant provides the written informed consent. The 
information is still discussed with both parties, and if the 
participant indicates that they would not like to partic-
ipate further then they are withdrawn from the study. 
Additionally, all participants are free to withdraw from 
the study at any time with no consequences to them now 
or in the future.
data management
All data obtained during the study, including data from 
hospital records (hard copy hospital records do not leave 
hospital), are entered into a password- protected elec-
tronic database (REDCap). Data are kept in a locked 
cabinet (hard copy) and stored on a password- protected 
server (electronic). The research team has access to hard 
copy data, and passwords are only known by members of 
the team who enter and analyse data. Data will be stored 
for a minimum of 5 years from study completion. A data 
monitoring committee is not used within this study as 
CCT interventions have no known risks. Any interim anal-
yses will be conducted by researchers not directly involved 
with the participants.
saliva sample collection
A saliva sample is collected from participants during the 
study to investigate the APOE4 allele genetic marker of 
cognitive impairment. The collection of saliva is non- 
invasive and poses no risk to the participant as drool is 
collected in an Oragene kit. This sample is taken at the 
most convenient time for the participant, usually during 
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their baseline session. It should be noted that only partic-
ipants who consent (tick the box in relation to the explic-
itly stated genetic marker testing on the consent form) 
will have genetic data extracted from their sample. The 
genetic data will be de- identified (reidentifiable) and 
stored in a password- protected file. Only a member of the 
research team or the research lab technician employed 
to analyse the sample has access to the tissue sample itself 
after data collection.
risks
The proposed intervention programme poses no addi-
tional risks to the participants as it does not interfere with 
their surgery or their cardiac rehabilitation. There have 
additionally been no risks of cognitive training interven-
tions noted in the literature. No data collection methods 
such as saliva, cognitive testing and electroencephalog-
raphy (which is part of a substudy not described here) 
pose any risks to participants.
There are small risks associated with home- based data 
collection for researchers; however, methods to lower 
this risk have been put in place. An initial hazard risk 
screening is conducted with the participant regarding 
their home and any possible risks (ie, dogs, housemates, 
stairs and so on). A log- in safety system is also used online 
where if the researcher fails to check in after a designated 
time (ie, 4 hours for baseline session), an emergency 
message is sent out to nominated contacts.
Ethical considerations
In the case that a participant scores within clinical ranges 
for any tests, a letter is sent to their general practitioner 
notifying them of the study and their result (if not within 
hospital), or the appropriate staff within the hospital are 
notified (eg, home treating team for delirious patients).
dissemination
It is anticipated that the results of this study will inform 
multiple publications and will be presented at multiple 
national and international conferences. As this is a topical 
area of research, results will be published throughout 
multiple stages of the study period and succeeding 
follow- ups, to ensure findings are communicated quickly 
and directly.
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